Ratings by Wolfe Research (Alexandria Hammond)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/9/2026 | Sanofi | SNY | New Coverage | Peerperform (N/A) |
40.23 (39.57) |
-1.64% | Details | |
| 10/9/2026 | GlaxoSmithKline | GSK | New Coverage | Outperform (N/A) |
46.54 (49.46) |
6.27% | Details | |
| 8/31/2026 | Protagonist Therapeutics | PTGX | Maintain | Outperform (N/A) |
|
Details | ||
| 8/25/2026 | Merck | MRK | Maintain | Outperform (N/A) |
|
Details | ||
| 8/25/2026 | Moderna | MRNA | Upgrade | Peerperform (Underperform) |
138.89 (226.89) |
63.36% | Details | |
| 8/13/2026 | Biogen | BIIB | Upgrade | Outperform (Peerperform) |
208.87 (233.48) |
11.78% | Details | |
| 8/13/2026 | Abbvie | ABBV | Upgrade | Outperform (Peerperform) |
248.76 (282.68) |
13.64% | Details | |
| 7/20/2026 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 5/21/2026 | Protagonist Therapeutics | PTGX | New Coverage | Outperform (N/A) |
100.88 (134.44) |
33.27% | Details | |
| 5/18/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/14/2026 | Biogen | BIIB | Maintain | Peerperform (N/A) |
|
Details | ||
| 5/4/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/19/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 3/18/2026 | Johnson & Johnson | JNJ | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2026 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 2/12/2026 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 2/5/2026 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2026 | Regeneron Pharma | REGN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2026 | Pfizer | PFE | Maintain | Underperform (N/A) |
|
Details | ||
| 1/28/2026 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 1/28/2026 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 1/8/2026 | Merck | MRK | Upgrade | Outperform (Peerperform) |
108.60 (143.63) |
32.26% | Details | |
| 1/8/2026 | Abbvie | ABBV | Downgrade | Peerperform (Outperform) |
233.42 (248.76) |
6.57% | Details | |
| 12/17/2025 | Pfizer | PFE | Maintain | Underperform (N/A) |
|
Details | ||
| 12/15/2025 | Gilead Sciences | GILD | Maintain | Outperform (N/A) |
|
Details | ||
| 10/15/2025 | Johnson & Johnson | JNJ | Maintain | Outperform (N/A) |
|
Details | ||
| 10/6/2025 | Johnson & Johnson | JNJ | Maintain | Outperform (N/A) |
|
Details | ||
| 9/22/2025 | Pfizer | PFE | Maintain | Underperform (N/A) |
|
Details | ||
| 9/3/2025 | Johnson & Johnson | JNJ | Maintain | Outperform (N/A) |
|
Details | ||
| 8/8/2025 | Eli Lilly | LLY | Maintain | Outperform (N/A) |
|
Details | ||
| 7/10/2025 | Johnson & Johnson | JNJ | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2025 | Moderna | MRNA | Maintain | Underperform (N/A) |
|
Details | ||
| 11/14/2024 | Bristol-Myers Squibb Co. | BMY | New Coverage | Peerperform (N/A) |
58.41 (58.83) |
0.72% | Details | |
| 11/14/2024 | Gilead Sciences | GILD | New Coverage | Outperform (N/A) |
92.63 (153.07) |
65.25% | Details | |
| 11/14/2024 | Johnson & Johnson | JNJ | New Coverage | Outperform (N/A) |
153.24 (253.79) |
65.62% | Details | |
| 11/14/2024 | Eli Lilly | LLY | New Coverage | Outperform (N/A) |
811.81 (1240.34) |
52.79% | Details | |
| 11/14/2024 | Moderna | MRNA | New Coverage | Underperform (N/A) |
42.14 (138.89) |
229.59% | Details | |
| 11/14/2024 | Merck | MRK | New Coverage | Peerperform (N/A) |
98.50 (108.60) |
10.25% | Details | |
| 11/14/2024 | Pfizer | PFE | New Coverage | Underperform (N/A) |
26.72 (29.44) |
10.18% | Details | |
| 11/14/2024 | Regeneron Pharma | REGN | New Coverage | Outperform (N/A) |
804.33 (782.04) |
-2.77% | Details | |
| 11/14/2024 | Biogen | BIIB | New Coverage | Peerperform (N/A) |
165.79 (208.87) |
25.98% | Details | |
| 11/14/2024 | Abbvie | ABBV | New Coverage | Outperform (N/A) |
170.35 (233.42) |
37.02% | Details |
